- Home
- VTGN vs PMVP Comparison
VTGN vs PMVP Comparison
Compare VTGN & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | PMVP |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.1M | 68.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VTGN | PMVP |
|---|---|---|
| Price | $4.24 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 1.0M | 262.9K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $721,000.00 | N/A |
| Revenue This Year | $54.26 | N/A |
| Revenue Next Year | $478.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.90 | $0.81 |
| 52 Week High | $5.14 | $1.84 |
Technical Indicators
Market Signals| Indicator | VTGN | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 41.76 |
| Support Level | $3.91 | $1.14 |
| Resistance Level | $4.60 | $1.30 |
| Average True Range (ATR) | 0.47 | 0.06 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 50.00 | 39.13 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.